12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Almirall, Menarini sales and marketing update

Almirall granted Menarini's Invida Holdings Pte. Ltd. rights to commercialize aclidinium bromide in Australia and New Zealand to treat chronic obstructive pulmonary disease (COPD). The deal includes rights to aclidinium bromide monotherapy and aclidinium bromide/formoterol combination. The European Commission and FDA approved aclidinium bromide in July. The product is approved in the...

Read the full 237 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >